Necessity of identifying the patterns of failure after concurrent radiochemotherapy part of a combined modality approach in patients with stage III non-small cell lung cancer [Sakai et al., Lung Cancer 2004;43:195–201]
Authors:
- Branislav JeremicBJBranislav Jeremic
- Frank ZimmermannFZFrank Zimmermann
- Carsten NiederCNCarsten Nieder
- Michael MollsMMMichael Molls
- 30 November 2004
- journal article
- other
- Published by Elsevier in Lung Cancer
- Vol. 46 (2) , 263-264
Abstract
No abstract availableThis publication has 4 references indexed in Scilit:
- Phase II study of bi-weekly docetaxel and carboplatin with concurrent thoracic radiation therapy followed by consolidation chemotherapy with docetaxel plus carboplatin for stage III unresectable non-small cell lung cancerLung Cancer, 2004
- Consolidation Docetaxel After Concurrent Chemoradiotherapy in Stage IIIB Non–Small-Cell Lung Cancer: Phase II Southwest Oncology Group Study S9504Journal of Clinical Oncology, 2003
- Concurrent Cisplatin, Etoposide, and Chest Radiotherapy in Pathologic Stage IIIB Non–Small-Cell Lung Cancer: A Southwest Oncology Group Phase II Study, SWOG 9019Journal of Clinical Oncology, 2002
- Twice-Weekly Paclitaxel and Weekly Carboplatin With Concurrent Thoracic Radiation Followed by Carboplatin/Paclitaxel Consolidation for Stage III Non–Small-Cell Lung Cancer: A California Cancer Consortium Phase II TrialJournal of Clinical Oncology, 2001